Multiple studies have shown reductions in inflammatory markers among people taking GLP-1 agonists, and patients frequently report improvements in inflammation-related conditions
The time it takes for your body to replenish its glutathione stores varies based on your diet, age, and overall health
GLP-1RA therapy, when prolonged and potent, may lead to a form of iatrogenic ERM : Short-term gains: lower glucose, lower weight, lower cardiovascular risk Long-term risks: impaired amino-acid balance, reduced re-anabolism, muscle loss, frailty, diminished resilience This progression can be subtle and clinically silentbiochemically detectable long before symptoms appear
Lexaria Bioscience Corp.s patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery
Here are some of the most commonand preventablemistakes researchers make that compromise their peptides